These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 23321055

  • 1. Response to low-dose desmopressin by a subcutaneous route in children with type 1 von Willebrand disease.
    Akin M.
    Hematology; 2013 Mar; 18(2):115-8. PubMed ID: 23321055
    [Abstract] [Full Text] [Related]

  • 2. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M, Karapinar DY, Balkan C, Ay Y, Kavakli K.
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [Abstract] [Full Text] [Related]

  • 3. Quantitative analysis of desmopressin (DDAVP) response in adult patients with type 1 von Willebrand disease.
    Guddati AK, Rosovsky RP, Van Cott EM, Kuter DJ.
    Int J Lab Hematol; 2019 Jun; 41(3):325-330. PubMed ID: 30735311
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.
    Hanebutt FL, Rolf N, Loesel A, Kuhlisch E, Siegert G, Knoefler R.
    Haemophilia; 2008 May; 14(3):524-30. PubMed ID: 18284449
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 May; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders.
    Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP.
    Br J Haematol; 2000 Jun; 109(4):865-9. PubMed ID: 10929043
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 18. von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD.
    Atiq F, Schütte LM, Looijen AEM, Boender J, Cnossen MH, Eikenboom J, de Maat MPM, Kruip MJHA, Leebeek FWG.
    Blood Adv; 2019 Dec 23; 3(24):4147-4154. PubMed ID: 31834934
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.